Safety and Efficacy of Brolucizumab in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis

CONCLUSION: Brolucizumab is a new drug that has potential advantages in efficacy over other anti-VEGF agents in the treatment of DME and DR. It showed significant improvement in BCVA and CSMT with the possibility of a lower dosing schedule compared to other agents. Although observed in low frequency, sight-threatening adverse effects appear to occur more frequently compared to other anti-VEGF agents. The main observed adverse event was retinal vasculitis which was seen more commonly with the 3 mg dose versus the 6 mg dose.PMID:37849309 | DOI:10.1080/08820538.2023.2271095

Source: Seminars in Ophthalmology - October 18, 2023 Category: Opthalmology Authors: Hashem Abu Serhan Mohammad J J Taha Mohammad T Abuawwad Abdelaziz Abdelaal Sara Irshaidat Leen Abu Serhan Qusai Faisal Abu Salim Nour Awamleh Basel Abdelazeem Ayman G Elnahry Source Type: research